Hanson Wade Have Taken the Decision to Cancel this Meeting.
Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
The Head and Neck Cancer Drug Development Summit has been curated with the industry in mind. Development in the H&N cancer space has entered the most active period to date, with emerging immunotherapy biotechs, biopharma, and pioneering academics racing to exploit this immunogenic tumor, validate early clinical data from broader solid tumor trials, and improve clinical outcomes in this indication with a high unmet medical need.
Tackle critical challenges in head and neck cancer including:
- Analyzing the role of the tumor in pathogenesis and treatment response
- Understanding the mechanisms of inherent and acquired resistance
- Discovering where promising avenues for targeted drug approaches for both HPV-positive and -negative subtypes are
- Uncovering how we can tailor the treatment journey to leverage the advantages of HPV-specific immunotherapy, immune checkpoint inhibitors, chemoradiotherapy, and improve patient outcomes